Tri Locum Partners LP Takes $3.61 Million Position in Vera Therapeutics, Inc. $VERA

Key Points

• Tri Locum Partners LP has invested approximately $3.61 million in Vera Therapeutics by acquiring 150,207 shares, making it the fund's 18th largest holding at 1.9% of its portfolio.
• Vera Therapeutics reported a loss of ($1.20) EPS for the last quarter, missing consensus estimates, and analysts predict an EPS of (-2.89) for the current year.
• Insider activity includes Director Patrick G. Enright acquiring over 209,000 shares, raising his total holdings in the company to valued at approximately $74.5 million.

Tri Locum Partners LP purchased a new position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 150,207 shares of the company's stock, valued at approximately $3,608,000. Vera Therapeutics accounts for approximately 1.9% of Tri Locum Partners LP's investment portfolio, making the stock its 18th biggest holding. Tri Locum Partners LP owned approximately 0.24% of Vera Therapeutics at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Price T Rowe Associates Inc. MD raised its position in shares of Vera Therapeutics by 8.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,754,832 shares of the company's stock worth $114,212,000 after buying an additional 377,783 shares during the period. T. Rowe Price Investment Management Inc. grew its stake in shares of Vera Therapeutics by 18.4% during the first quarter. T. Rowe Price Investment Management Inc. now owns 1,675,367 shares of the company's stock valued at $40,243,000 after acquiring an additional 260,188 shares in the last quarter. Paradigm Biocapital Advisors LP grew its stake in shares of Vera Therapeutics by 31.0% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 1,437,339 shares of the company's stock valued at $60,785,000 after acquiring an additional 340,488 shares in the last quarter. Woodline Partners LP grew its stake in Vera Therapeutics by 20.1% in the fourth quarter. Woodline Partners LP now owns 1,202,466 shares of the company's stock worth $50,852,000 after purchasing an additional 201,573 shares in the last quarter. Finally, Integral Health Asset Management LLC grew its stake in Vera Therapeutics by 130.0% in the fourth quarter. Integral Health Asset Management LLC now owns 1,150,000 shares of the company's stock worth $48,634,000 after purchasing an additional 650,000 shares in the last quarter. Hedge funds and other institutional investors own 99.21% of the company's stock.

Vera Therapeutics Stock Performance

Shares of Vera Therapeutics stock traded down $0.65 during midday trading on Monday, hitting $21.64. The company had a trading volume of 2,121,800 shares, compared to its average volume of 1,796,484. The business's 50 day simple moving average is $22.19 and its two-hundred day simple moving average is $23.52. The stock has a market cap of $1.38 billion, a PE ratio of -6.04 and a beta of 1.17. The company has a debt-to-equity ratio of 0.16, a current ratio of 17.03 and a quick ratio of 17.03. Vera Therapeutics, Inc. has a 1-year low of $18.53 and a 1-year high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($1.20) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.38). During the same quarter last year, the business earned ($0.62) EPS. As a group, equities analysts predict that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on VERA shares. Scotiabank reiterated an "outperform" rating on shares of Vera Therapeutics in a research note on Tuesday, June 3rd. HC Wainwright reaffirmed a "buy" rating and set a $85.00 price target (up previously from $75.00) on shares of Vera Therapeutics in a report on Monday, June 2nd. Guggenheim reissued a "buy" rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. Wedbush decreased their price target on shares of Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Finally, Wolfe Research reiterated a "peer perform" rating on shares of Vera Therapeutics in a research report on Monday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $63.00.

Insiders Place Their Bets

In other news, Director Patrick G. Enright acquired 40,607 shares of the firm's stock in a transaction on Tuesday, June 24th. The shares were purchased at an average cost of $22.35 per share, with a total value of $907,566.45. Following the completion of the purchase, the director owned 3,596,593 shares of the company's stock, valued at $80,383,853.55. This represents a 1.14% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 16.30% of the company's stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.